CJC-1295 research guide for Travers. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
The pursuit for CJC-1295 in Travers almost always leads to the same conclusion: research peptides are supplied via specialist online vendors, not brick-and-mortar outlets. What this means for Travers researchers is that geography is secondary to your ability to verify analytical documentation — and those evaluation tools are within reach of all serious researchers. The primary quality indicators for CJC-1295 are HPLC purity ≥98%, molecular identity verified through mass spectrometry, and a bacterial endotoxin panel — all documented in a lot-traced Certificate of Analysis. This guide walks Travers researchers through that evaluation process and explains what quality documentation for CJC-1295 should look like.
What Studies Say About CJC-1295
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Travers studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
How to Source CJC-1295 — Vendor Guide
Before looking at individual vendors, build a clear picture of what a proper COA looks like — so you can recognise whether a vendor meets it. A COA for CJC-1295 should include: HPLC purity percentage with the underlying chromatogram, mass spectrometry data verifying the correct molecular weight, endotoxin test results, and a residual solvent panel — all traceable to your batch. Positive vendor signals beyond COA quality: established track record of at least two years, responsive technical support who understand testing methodology, and temperature-appropriate packaging with desiccant. Store lyophilised CJC-1295 at minus 20 degrees Celsius until ready to use; reconstitute only the amount needed for the near-term protocol and keep the remainder frozen.
Order CJC-1295 — ships to Travers
COA-verified · International tracking · Research grade
Research compound status for CJC-1295 means safety data comes from animal studies, in-vitro work, and limited human observations — rather than the controlled trials that generate pharmaceutical safety profiles. Temperature excursions — even short periods above −20°C — can partially degrade CJC-1295 without any obvious sign; always maintain cold chain and work with cold-shipped material. Bacterial endotoxin contamination is the primary safety concern specific to research peptides — verify endotoxin testing is present in the lot-matched certificate before any injectable research application. Researchers combining CJC-1295 with other compounds should examine published studies for potential interaction data before running stacked compound experiments.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
